News

Research into key drivers of fibrosis will be used by a Singapore-funded biotechnology start-up, Enleofen Bio, to possibly develop first-in-class therapeutics for pulmonary fibrosis (PF) and other fibrosis-related diseases. The intellectual property that came from the work performed at two Singapore institutions, Duke-NUS Medical School (Duke-NUS) and National Heart Centre…

The British Lung Foundation (BLF), in collaboration with GlaxoSmithKline (GSK) has awarded £1.3 million (about $1.68 million) in grants to three lung disease experts to support research projects on finding new therapeutic targets for personalized medicine in idiopathic pulmonary fibrosis (IPF), bronchiectasis and chronic obstructive pulmonary disease (COPD). “Our professorships…

Doctors increasingly recognize nutrition as a key factor in improving overall function, exercise tolerance and quality of life in patients with pulmonary fibrosis and other lung diseases. With that in mind, a team has reviewed current literature and summarized nutritional goals for lung disease patients. The review titled “Nutrition…

A first clinical trial of the safety and tolerability of a potential treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases —  PAT-1251, being developed by PharmAkea — was successfully completed in healthy volunteers, the company announced. PAT-1251 is an investigational small-molecule designed to specifically inhibit the LOXL2 enzyme. Patients with fibrotic illnesses,…

Ethris has joined efforts with AstraZeneca and its biologics research and development arm MedImmune to develop novel mRNA-based therapies for respiratory diseases such as idiopathic pulmonary fibrosis (IPF), asthma, and chronic obstructive pulmonary disease (COPD). Under the terms of the five-year research agreement, Ethris will receive 25 million euros…

The Australian company AdAlta will present new information on its idiopathic pulmonary fibrosis therapy AD-114 at the IPF Summit in Boston on Aug. 23. CEO Sam Cobb’s presentation will be titled “i-Bodies: A Novel Therapeutic Approach for IPF.” The three-day conference started Aug. 21. “IPF is a disease with high unmet clinical…

Context Therapeutics, a Philadelphia-based biotech, is collaborating with three leading institutions for research into the Sigma1 protein and its role in diseases. The institutions are Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Institute, and Fondation Synergie Lyon Cancer. The Sigma1 protein helps regulate the immune system and create stability…

Prometic recently announced a financial agreement and partnership with Shenzhen Royal Asset Management (SRAM) to develop, manufacture, and commercialize several of its anti-fibrotic products in China, including PBI-4050 for idiopathic pulmonary fibrosis (IPF). PBI-4050 is an anti-fibrotic oral drug, which has demonstrated positive results in a Phase 2 study (NCT02538536) in patients…

The Chicago-based Pulmonary Fibrosis Foundation (PFF) will hold its inaugural PFF Walk on Sept. 9 to mark PF Awareness Month. More than 400 individuals and 80 teams from across the United States have registered for the event at Chicago’s Lincoln Park. In addition, “virtual walks” will take place throughout the nation…

GLPG1690, an investigational therapy developed by Galapagos to treat idiopathic pulmonary fibrosis (IPF), prevented further lung decline in a Phase 2a trial, allowing the Belgian pharmaceutical firm to rapidly move forward with the clinical development of this therapy. The trial, called FLORA (NCT02738801), involved randomly assigning 17 IPF patients treatment with GLPG1690 and…